Excited and grateful that we received $500K from an angel investor, enabling us to move forward with our CLIA LDT certification and prototype testing for CAL, a first-in-class precision cancer diagnostic instrument.
top of page
EMPIRI INC.
Search
Updated: Feb 15, 2022
EMPIRI's co-founder Dr. Kyuson Yun will be presenting at the AACR, mini-symposium session "Ex Vivo Models for Understanding Genetic Variation, Metastasis, and Treatment Sensitivity" on our platform technology, "E-slice: A novel 3D culture platform for precision medicine". #medicine #technology #culture #precisionmedicine #precisiononcology #cancerdiagnostics #aacr #drugdevelopment #drugdiscovery #pharmaceutical
bottom of page